Soligenix Inc., formerly known as DOR BioPharma Inc., a late-stage biotechnology company, today announced it has formed a consortium to develop technology to enhance acting vaccines, including RiVax, the company’s proprietary vaccine for ricin toxin, which can be used as a biological weapon. Soligenix also announced it was awarded a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to continue this work.

The announced consortium draws together industry and academic researchers from various disciplines, including the University of Colorado, the University of Kansas, and the Tulane National Primate Research Center, SRI International, Health Research Inc, Battelle Memorial Institute, Nanotherapeutics, and BioCon Inc.

“Each of our academic and industry consortium members brings impressive expertise to our vaccine stabilization program,” Dr. Robert N. Brey, PhD, chief scientific officer of Soligenix stated in the press release. “This association has the potential

ImmunoGen, Inc. (NASDAQ:IMGN) has announced that Amgen, Inc. (NASDAQ:AMGN)Inc has licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology for the development of anticancer therapeutics to an undisclosed target. This is the second such license to be taken by Amgen – the company licensed the exclusive right to use ImmunoGen’s TAP technology for another undisclosed cancer target in September 2009.

Amgen Inc. is one of the leading biotechnology companies that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The Company markets human therapeutic products in the areas of supportive cancer care, nephrology and inflammation. While announcing the news, CEO and President of ImmunoGen Inc, Daniel Junius commented that the Company undertook extensive diligence prior to taking the first

TapImmune, Inc. is a biotechnology company focused on developing innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine, moves characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, making it impossible for the immune system to spot rogue cells and cancerous cells, allowing them to grow undetected.

The company’s vaccine has demonstrated its effectiveness in restoring TAP which in-turn restores and augments the characteristic marker (antigen) and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an accelerant to enhance targeted vaccines against infectious diseases. For example, including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1,000 times.

TapImmune’s technologies have broad applications in developing therapeutic and preventative vaccines. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday November 18, 2009

DrStockPick.com Stock Report!

PWRM, Power 3 Medical Products Inc, PWRM.OB

PGCX, Pangenex Corporation, PGCX.PK

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical PWRM continued to rally for the 2nd day in a row closing at $0.17 hitting a 52 week high of $0.22 on the way. PWRM’s volume has also performed trading over 36 million shares today by the time the closing bell rang.

Those of you who put

Today we are featuring top-performing “Health" equity mutual funds , which primarily invest in equity securities of healthcare and related companies.

Investors can find such funds by checking out the entire list of the Zacks #1 Rank Health Equity Funds.

3 Healthy Picks

Eaton Vance Worldwide Health Sciences A (ETHSX) long-term capital growth by investing in a global and diversified portfolio of health sciences companies. It was incepted in July 1985.

The fund pursues its objective by investing in worldwide health sciences portfolio. The fund invests primarily in common stocks of companies engaged in the development, production or distribution of products related to scientific advances in health care and companies with a broad range of market capitalization's, including small companies.

The fund has an expense ratio of 2.06% and a portfolio turnover of 48% as May 2009. The fund offers dividends and capital gains annually.

Samuel D. Isaly has been lead manager of the fund since

GlaxoSmithKline (GSK) and Nabi Biopharmaceuticals (NABI) signed a licensing agreement for a nicotine conjugate vaccine (NicVAX) as well as for the development of a second generation nicotine vaccine. NicVAX is an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse. Earlier in October, the vaccine received a $10 million grant from the National Institute on Drug Abuse.

As per the agreement, Nabi will get an upfront payment of $40 million and is eligible to receive more than $500 million (together with upfront payment) as option fees and milestones for the vaccine, NicVAX, and follow-on nicotine vaccines. Nabi has the potential to receive double-digit royalties from sales if the product is commercialized. GlaxoSmithKline will have an option to exclusively in-license NicVAX on a worldwide basis and a license to develop follow-on next-generation nicotine vaccines using Nabi's intellectual property together with GSK's own technology.

NicVAX is currently

ArQule Inc (NASDAQ:ARQL) has presented their data at the AACR-NCI-EORTC meeting in Boston which clearly demonstrates the capabilities of Company’s proprietary drug discovery platform to generate a class of small molecules that has significant therapeutic potential. The data reflected the results of the application of the ArQule Kinase Inhibitor Platform (AKIP) to discover and optimize a series of small molecule inhibitors of fibroblast growth factor receptor (FGFR) that are not ATP-competitive and that show potent anti-tumor activity in FGFR-driven cancer models.

ArQule is a biotechnology company which looks after the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™)

Nov. 17, 2009 (PR Newswire) — CORALVILLE, Iowa, Nov. 17 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced that its Board of Directors approved a dividend of shares of common stock of HealthAmerica, Inc., a Nevada corporation of which Vivakor owns approximately 84% of the outstanding common stock. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on the record date. The record date for the distribution is expected to be December 1, 2009, subject to review and approval of FINRA, and the distribution date is expected to be December 9, 2009. After the dividend distribution, Vivakor will continue to own approximately 62% of the outstanding common stock of HealthAmerica.

Vivakor shareholders will not be required to take any action to receive the HealthAmerica common shares on the distribution date.

Vivakor Chairman Matt Nicosia

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday November 16, 2009

DrStockPick.com Stock Report!

NVAX, PWRM

**************************************************************

NVAX, Novavax Inc.

NVAX is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.

NVAX announced today that enrollment has been completed in the first stage of a two-stage

For Immediate Release

Chicago, IL – November 16, 2009 – Zacks Equity Research highlights Infosys (INFY) as the Bull of the Day and Myriad Genetics Inc. (MYGN) the Bear of the Day. In addition, Zacks Equity Research provides analysis on American International Group (AIG), Citigroup (C) and Bank of America (BAC).

Full analysis of all these stocks is available at http://at.zacks.com/?id=5506

Here is a synopsis of all five stocks:

Bull of the Day:

We are upgrading Infosys (INFY) to an Outperform rating with a target price of $57. Through the ongoing economic downturn, the company has invested in Research & Development as well as intellectual property-based solutions. It continues to focus on large deals targeted at organizational transformation where there is a dearth of vendor talent.

The company continues to win new customers and manages to keep its order book healthy.